1 completed, 1 not yet recruiting, 1 recruiting. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
Follow VLP Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant - Randomised Clinical Trial, Double Blind | Phase 1 | Not yet recruiting | VLP Therapeutics | 42 | 2027-01-04 | 2026-09-21 |
| Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection), Pembrolizumab (KEYTRUDA®), VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection) - Head and Neck Cancers- Squamous Cell, Head and Neck Cancer | Phase 1 | Recruiting | VLP Therapeutics | 41 | 2025-05-13 | 2026-09-21 |
| To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers 5 microgram VLPM01, 15 microgram VLPM01, 30 microgram VLPM01 - Malaria,Falciparum | Phase 1 | Completed | VLP Therapeutics | 36 | 2019-03-13 | 2021-04-08 |
Carcinoma, Squamous Cell (1) · Dengue (1) · Head and Neck Neoplasms (1) · Malaria, Falciparum (1) · Mouth Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Sodium Chloride (1) · pembrolizumab (1)
United States (3)
Fred M Baik, MD (1)